Abstract | BACKGROUND: Acute hepatitis E is associated with a higher rate of mortality as compared to hepatitis A or B infections in some series. To date no treatment has been recommended for acute hepatitis E. However, ribavirin has been recently reported to be highly effective to treat solid-organ-transplant recipients chronically infected with hepatitis E virus (HEV). OBJECTIVE AND STUDY DESIGN: RESULTS: Liver biological tests showed rapid improvement concurrently with a decrease in HEV RNA levels in serum samples. Therapy was interrupted after 21 days. At that time, ALT had normalized, bilirubinemia was 138 μmol/L, and HEV RNA was almost undetectable in the serum. CONCLUSION:
|
Authors | René Gerolami, Patrick Borentain, Ferdaous Raissouni, Anne Motte, Caroline Solas, Philippe Colson |
Journal | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
(J Clin Virol)
Vol. 52
Issue 1
Pg. 60-2
(Sep 2011)
ISSN: 1873-5967 [Electronic] Netherlands |
PMID | 21764632
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2011 Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- Hepatitis Antibodies
- RNA, Viral
- Ribavirin
|
Topics |
- Acute Disease
- Antiviral Agents
(therapeutic use)
- Hepatitis Antibodies
(blood)
- Hepatitis E
(drug therapy)
- Humans
- Liver
(pathology)
- Liver Function Tests
- Male
- Middle Aged
- RNA, Viral
(blood)
- Ribavirin
(therapeutic use)
|